Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

18Buy

4Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$826Upside to Avg. PT+1.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$960→$980
Oct 19, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$854→$865
Oct 15, 2026	UBS	Trung Huynh	Upgrade	Neutral→Buy	$660→$978
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$737→$810
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$772→$780
Oct 7, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$758→$779
Oct 6, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$900→$950
Oct 1, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$870→$930
Oct 1, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$850
Sep 29, 2026	RBC Capital	Brian Abrahams	Maintained	Sector Perform	$737
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$800→$920
Aug 17, 2026	Leerink Partners	David Risinger	PT Raise	Market Perform	$641→$824
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$700→$740
Aug 3, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$1000→$1030
Jul 31, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$696→$737
Jul 31, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$730→$758
Jul 31, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$750→$795
Jul 31, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$700→$750
Jul 31, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$769→$772
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$995→$1000

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980

TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $960 to $980.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.

Benzinga Newsdesk

PRO
UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978

UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $758 to $779.

Benzinga Newsdesk

Regeneron Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980

PRO
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

PRO
UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

People Also Watch

People Also Watch

Regeneron Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980

PROPiper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

PROUBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978

PRORBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PROTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PROMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

People Also Watch

People Also Watch

PRO
TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980

PRO
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

PRO
UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779